Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
BMS’ ELOQUENT-1 Phase III study fails to meet primary endpoint
The primary endpoint of the study was to determine whether the addition of Empliciti to Revlimid and low-dose dexamethasone would improve progression-free survival. Credit: KGH.
Learn more
Hover over the logos to learn more about the companies who made this project possible.
Close
-
SOM Biotech
SOM Biotech is an Artificial Intelligence AI drug discovery and...
About
SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology.
FollowMake an Enquiry
-
Jeeva Informatics Solutions
Jeeva Informatics Solutions (Jeeva) is a seed-stage start-up on a...
About
Jeeva Informatics Solutions (Jeeva) is a seed-stage start-up on a mission to develop artificial intelligence (AI)-driven decentralised clinical trials and optimise patient-focused clinical research.
FollowMake an Enquiry
-
SynapCon
SynapCon specialises in the development of innovative software solutions for...
About
SynapCon specialises in the development of innovative software solutions for clinical trial and medical research project management.
FollowMake an Enquiry